$DRTS
Alpha Tau Medical Ltd. Stock $drts

$drts Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024020767 Filed on March 07, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.453M	$9.256M	$11.25M
YoY Change	-5.83%	-17.7%	379.98%
% of Gross Profit
Research & Development	$7.490M	$26.42M	$20.89M
YoY Change	39.22%	26.49%	82.49%
% of Gross Profit
Depreciation & Amortization	$564.0K	$1.074M	$979.0K
YoY Change	11.9%	9.7%	26.16%
% of Gross Profit
Operating Expenses	$9.943M	$35.68M	$32.14M
YoY Change	24.52%	11.03%	133.04%
Operating Profit		-$35.68M	-$32.14M
YoY Change		11.03%	133.04%
Interest Expense	$2.586M	$4.545M	$2.203M
YoY Change	-43.68%	106.31%	-1196.02%
% of Operating Profit
Other Income/Expense, Net		$1.994M	$16.55K
YoY Change		11950.52%	-100.12%
Pretax Income	-$7.357M	-$29.14M	-$33.74M
YoY Change	116.83%	-13.64%	23.76%
Income Tax	$8.000K	$16.00K	$20.00K
% Of Pretax Income
Net Earnings	-$7.365M	-$29.16M	-$33.76M
YoY Change	116.87%	-13.64%	23.8%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.42	-$0.53
Diluted Earnings Per Share	-$0.11	-$0.42	-$0.53
COMMON SHARES
Basic Shares Outstanding	69.67M shares	69.38M shares	63.53M shares
Diluted Shares Outstanding		69.38M shares	63.53M shares

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.79M	$81.79M	$104.5M
YoY Change	-21.76%	-21.76%	233.79%
Cash & Equivalents	$12.66M	$12.66M	$5.836M
Short-Term Investments	$69.13M	$69.13M	$98.69M
Other Short-Term Assets	$3.968M	$3.949M	$1.915M
YoY Change	103.8%	106.21%	46.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$85.76M	$85.76M	$106.5M
YoY Change	-19.46%	-19.46%	226.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.16M	$21.16M	$13.28M
YoY Change	183.24%	59.33%	76.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$471.0K	$471.0K	$391.0K
YoY Change	20.46%	20.46%	-80.72%
Total Long-Term Assets	$21.63M	$21.63M	$13.67M
YoY Change	58.22%	58.22%	42.8%
TOTAL ASSETS
Total Short-Term Assets	$85.76M	$85.76M	$106.5M
Total Long-Term Assets	$21.63M	$21.63M	$13.67M
Total Assets	$107.4M	$107.4M	$120.1M
YoY Change	-10.62%	-10.62%	184.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.040M	$2.566M	$1.423M
YoY Change	324.46%	80.32%	13.75%
Accrued Expenses	$1.062M	$4.457M	$2.852M
YoY Change	-16.77%	56.28%	-9.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.102M	$7.102M	$4.338M
YoY Change	63.72%	63.72%	-1.52%
LONG-TERM LIABILITIES
Long-Term Debt	$5.610M	$5.610M	$0.00
YoY Change
Other Long-Term Liabilities	$10.20M	$10.20M	$10.15M
YoY Change	0.46%	0.46%	-45.48%
Total Long-Term Liabilities	$15.81M	$15.81M	$10.15M
YoY Change	55.71%	55.71%	-45.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.102M	$7.102M	$4.338M
Total Long-Term Liabilities	$15.81M	$15.81M	$10.15M
Total Liabilities	$22.91M	$22.91M	$14.49M
YoY Change	58.11%	58.11%	-37.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$115.8M
YoY Change	33.67%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.48M	$84.48M	$105.7M
YoY Change
Total Liabilities & Shareholders Equity	$107.4M	$107.4M	$120.1M
YoY Change	-10.62%	-10.62%	184.61%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$7.365M	-$29.16M	-$33.76M
YoY Change	116.87%	-13.64%	23.8%
Depreciation, Depletion And Amortization	$564.0K	$1.074M	$979.0K
YoY Change	11.9%	9.7%	26.16%
Cash From Operating Activities	-$8.038M	-$17.96M	-$23.88M
YoY Change	-6.0%	-24.8%	102.16%
INVESTING ACTIVITIES
Capital Expenditures	$5.811M	$6.401M	$904.0K
YoY Change	2437.55%	608.08%	-130.88%
Acquisitions
YoY Change
Other Investing Activities	$19.52M	$25.08M	-$89.03M
YoY Change	557.78%	-128.17%	-501.05%
Cash From Investing Activities	$13.71M	$18.68M	-$89.94M
YoY Change	400.62%	-120.77%	-566.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$49.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.297M	5.297M	$96.91M
YoY Change	4944.76%	-94.53%	87201.8%
NET CHANGE
Cash From Operating Activities	-8.038M	-17.96M	-$23.88M
Cash From Investing Activities	13.71M	18.68M	-$89.94M
Cash From Financing Activities	5.297M	5.297M	$96.91M
Net Change In Cash	10.97M	6.021M	-$17.17M
YoY Change	-292.24%	-135.07%	-326.73%
FREE CASH FLOW
Cash From Operating Activities	-$8.038M	-$17.96M	-$23.88M
Capital Expenditures	$5.811M	$6.401M	$904.0K
Free Cash Flow	-$13.85M	-$24.36M	-$24.78M
YoY Change	57.73%	-1.71%	178.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41316
CY2023	dei	Entity Registrant Name EntityRegistrantName	Alpha Tau Medical Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Kiryat HaMada St. 5
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Jerusalem
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	9777605
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69670612	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1281
CY2023	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5836000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12657000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	850000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	98694000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	69131000	usd
CY2023Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	3152000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1097000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	816000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	106477000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	85756000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	391000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	471000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7471000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12798000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5810000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8363000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	13672000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	21632000	usd
CY2022Q4	us-gaap	Assets Assets	120149000	usd
CY2023Q4	us-gaap	Assets Assets	107388000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1423000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2566000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2246000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3474000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	669000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1062000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4338000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7102000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	5610000	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	5630000	usd
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	3597000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4524000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6604000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10154000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15811000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14492000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	22913000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	362116800	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	362116800	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69105000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69105000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69670612	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69670612	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192259000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200234000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86602000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115759000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	105657000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	84475000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120149000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107388000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11447000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20890000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26424000	usd
CY2021	us-gaap	Marketing Expense MarketingExpense	482000	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	974000	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	1924000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1861000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10272000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7332000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13790000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-32136000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-35680000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13474000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1606000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6539000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27264000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33742000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29141000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29157000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27271000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33762000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29157000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63534875	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69377922	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8429000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	111000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	812000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-34777000	usd
CY2022	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3335000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	74952000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	53964000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	35170000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6748000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	105657000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	49000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7926000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29157000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	84475000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29157000	usd
CY2021	us-gaap	Depreciation Depreciation	776000	usd
CY2022	us-gaap	Depreciation Depreciation	979000	usd
CY2023	us-gaap	Depreciation Depreciation	1074000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	812000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6748000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7926000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-29000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1325000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1740000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-157000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	341000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-281000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1889000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1637000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	80000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	13257000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3788000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2033000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	239000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	220000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1143000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2078000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1206000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1228000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1152000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-809000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-535000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-729000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11812000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23879000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17958000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	8082000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	121137000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	163629000	usd
CY2023	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	3152000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	30282000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32105000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	191864000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2927000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	904000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6401000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19273000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89936000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18682000	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	5248000	usd
CY2022	drts	Proceeds From Spac Merger And Pipe Financing Net Of Transaction Cost ProceedsFromSPACMergerAndPIPEFinancingNetOfTransactionCost	93543000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3335000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	111000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96905000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5297000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-258000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7680000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17168000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5971000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16174000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23854000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6686000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23854000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6686000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12657000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	16000	usd
CY2021	drts	Interest Received InterestReceived	351000	usd
CY2022	drts	Interest Received InterestReceived	237000	usd
CY2023	drts	Interest Received InterestReceived	6160000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	52000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3304000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">NOTE 1: - GENERAL</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">a.</td><td style="text-align: justify">Company description:</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November 2015 and began its operations in January 2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera Medical Ltd., (“Althera”), developed in 2003 at Tel Aviv University.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In August 2017 the Company established a fully owned subsidiary in the United States - “Alpha Tau Medical Inc.” (“ATM Inc.”). ATM Inc. began its activity in August 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In January 2018 the Company established a subsidiary in Japan “Alpha Tau Medical KK” (hereafter: ATM KK). ATM KK began its activity in January 2018. Since July 2019, the Company holds 100% of ATM KK.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In July 2019, the Company established a fully owned subsidiary in Canada “Alpha Tau Medical Canada Inc.” (“ATM Canada Inc.”). ATM Canada Inc. began its activity in March 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">b.</td><td style="text-align: justify">Merger with Healthcare Capital Corp:</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">On July 7, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Healthcare Capital Corp., a Delaware corporation (“HCCC”), and Archery Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”). As result of the Merger Agreement, the Merger Sub was merged with and into HCCC (the “Merger”) on March 7, 2022 (the “Closing Date”), with HCCC surviving the merger as a wholly owned subsidiary of the Company and the Company’s Ordinary shares, no par value per share and Public and Private Warrants (see note 8) began trading on the Nasdaq Capital Market on March 8, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Concurrently with and following the execution of the Merger Agreement, the Company entered into Subscription Agreements, together with a number of subsequent agreements since with certain investors (the “PIPE Investors”), in which the Company consummated the sale of 9,251,006 Ordinary shares for gross proceeds of $92,510.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -0.75pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Total gross proceeds resulted from the Merger transaction were approximately $104,052, out of which total transaction costs amounted to approximately $5,713. The transaction costs related to the Warrants liability in the amount of $817 were recognized as expenses in the Company’s consolidated statements of operations. The residual amount was recognized as additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The Merger has been accounted for as a recapitalization, with no goodwill or other intangible assets recorded. It has been determined that the Company is the accounting acquire.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">c.</td><td style="text-align: justify">The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to secure financing; obtain further marketing approvals from regulatory authorities; access potential markets; and build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">As of December 31, 2023, the Company had cash, cash equivalents, short-term deposits and restricted deposits of $84,940. During the year ended December 31, 2023, the Company incurred a net loss of $29,157 and had negative cash flows from operating activities of $17,958. In addition, the Company had an accumulated deficit of $115,759 on December 31, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least two years.</p>
CY2023	drts	Gross Proceeds GrossProceeds	104052000	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	5713000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	84940000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29157000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17958000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115759000	usd
CY2023	drts	Liquidity Requirements LiquidityRequirements	P2Y
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">a.</td><td style="text-align: justify">Use of estimates for the preparation of financial statements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair values of warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5836000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12657000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	850000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6686000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12657000	usd
CY2023Q4	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P1Y
CY2021	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	2459000	usd
CY2022	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	1343000	usd
CY2023	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	841000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.50	pure
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">r.</td><td style="text-align: justify">Concentration of credit risks:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits and restricted deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Cash, cash equivalents, restricted cash, short-term deposits and restricted deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p>
CY2023	drts	Severance Pay Deposit Rate SeverancePayDepositRate	8.33%
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	318000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	418000	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	466000	usd
CY2022Q1	drts	Assets And Lease Liabilities AssetsAndLeaseLiabilities	6089000	usd
CY2023	drts	Recently Issued Accounting Pronouncements Not Yet Adopted RecentlyIssuedAccountingPronouncementsNotYetAdopted	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 56.7pt"></td><td style="width: 28.35pt">x.</td><td style="text-align: justify">Recently issued accounting pronouncements not yet adopted:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">As an “emerging growth company”, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</p>
CY2022Q4	drts	Government Authorities Receivable GovernmentAuthoritiesReceivable	281000	usd
CY2023Q4	drts	Government Authorities Receivable GovernmentAuthoritiesReceivable	325000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	784000	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	472000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	32000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	19000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1097000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	816000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	50000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9362000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15763000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1891000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2965000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7471000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12798000	usd
CY2021	us-gaap	Depreciation Depreciation	776000	usd
CY2022	us-gaap	Depreciation Depreciation	979000	usd
CY2023	us-gaap	Depreciation Depreciation	1074000	usd
CY2023	drts	Non Cancellable Term NonCancellableTerm	P49Y
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	775000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	995000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	18000	usd
CY2022	us-gaap	Lease Cost LeaseCost	793000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1045000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5810000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8363000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	669000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1062000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4524000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6604000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1097000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1040000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	899000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	894000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5841000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10671000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3005000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7666000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	907000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1159000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1276000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2236000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	63000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	79000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2246000	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9984	shares
CY2022	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	1160016	shares
CY2023	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	324	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2313976	shares
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3474000	usd
CY2023Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7904	ils
CY2023Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2054	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	20263	ils
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	5248	usd
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0046	pure
CY2023Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.015	pure
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	75000	usd
CY2023	drts	Long Term Debt Currency Exchange Expenses LongTermDebtCurrencyExchangeExpenses	338	usd
CY2023	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	In whole and not in part; ●At a price of $0.01 per warrant; ●Upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and ●If, and only if, the closing price of the Ordinary shares equals or exceeds $18.00 per share (subject to standard adjustments) for any 20 trading days within a 30-trading day period ending three business days before the Company sends to the notice of redemption to the warrant holders.
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	13739186	shares
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	14270797	shares
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	53964000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.87
CY2023Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	3880777	shares
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	3.87
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1556817	shares
CY2023Q4	drts	Short Term Bank Loans And Note Payable ShortTermBankLoansAndNotePayable	3152	usd
CY2023Q4	drts	Aggregate Amount aggregateAmount	5445	usd
CY2023	drts	Royalty Rate RoyaltyRate	0.07	pure
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.905292	pure
CY2023Q4	drts	Shares Number Of Votes SharesNumberOfVotes	1	pure
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	812000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6748000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7926000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14396000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	9.81
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	8.08
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	3.47
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.45
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.76
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.87
CY2023	drts	Warrants Issued To Investors Description WarrantsIssuedToInvestorsDescription	(i)As part of the 2018 SPA, the Company granted 9,053 Warrants to Ordinary shares to a public service foundation in Israel. The Warrants were exercised on July 15, 2021 into 9,053 Ordinary shares for no consideration. (ii)In July 2019, as part of the investment round of HekaBio K.K, the investors received 651,067 Warrants to Ordinary shares with an exercise price of $5.04 to be exercise within 4 years from grant date. During the year ended December 31, 2022, all 651,067 Warrants were exercised into 308,540 ordinary shares of the Company. (iii)Upon completion of the Merger, the 3,880,777 warrants convertible into Preferred A Shares of the Company were converted into an identical number of warrants convertible into ordinary shares of the Company until September 2024 at an exercise price of $3.87 (see also notes 2 n and 10 b).
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1556817	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9984	shares
CY2022	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	1160016	shares
CY2023	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	324	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2313976	shares
CY2016Q2	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	67897	shares
CY2016Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P7Y
CY2023Q1	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	67897	shares
CY2023Q1	drts	Number Of Warrants Exercised NumberOfWarrantsExercised	67897	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	642000	usd
CY2021	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	412000	usd
CY2023	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	210000	usd
CY2023	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	75000	usd
CY2021	drts	Fair Value Adjustment Of Warrants Expenses FairValueAdjustmentOfWarrantsExpenses	13257000	usd
CY2022	drts	Fair Value Adjustment Of Warrants Expenses FairValueAdjustmentOfWarrantsExpenses	3788000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	16000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	21000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	39000	usd
CY2021	drts	Total Financial Expenses TotalFinancialExpenses	13685000	usd
CY2022	drts	Total Financial Expenses TotalFinancialExpenses	3809000	usd
CY2023	drts	Total Financial Expenses TotalFinancialExpenses	324000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	413000	usd
CY2021	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	211000	usd
CY2022	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	1790000	usd
CY2023	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	4830000	usd
CY2023	drts	Remeasurement Of Warrants RemeasurementOfWarrants	-2033000	usd
CY2021	drts	Financial Income Total FinancialIncomeTotal	211000	usd
CY2022	drts	Financial Income Total FinancialIncomeTotal	2203000	usd
CY2023	drts	Financial Income Total FinancialIncomeTotal	6863000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13474000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1606000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6539000	usd
CY2023	drts	Reduced Tax Rates ReducedTaxRates	0.075	pure
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	27089000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	33100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	28224000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	175000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	916000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27264000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33742000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29141000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	20000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	16000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	56012000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	22000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	28000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1018000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1363000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	50000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	94000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	140000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	473000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1041000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3950000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4372000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5607000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6948000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5084000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5837000	usd
CY2022Q4	drts	Deferred Tax Assets Tax Deferred Expense Rou Asset DeferredTaxAssetsTaxDeferredExpenseROUAsset	523000	usd
CY2023Q4	drts	Deferred Tax Assets Tax Deferred Expense Rou Asset DeferredTaxAssetsTaxDeferredExpenseROUAsset	1111000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29157000	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63534875	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69377922	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25349049	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27234182	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29395579	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	13281000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	21161000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2021	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt		usd
CY2022	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt		usd
CY2023	drts	Fair Value Adjustment Of Warrants Expenses FairValueAdjustmentOfWarrantsExpenses		usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	265000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	982000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	114000	usd
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		usd
CY2022Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent		usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63534875	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69377922	shares
CY2021	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet		usd
CY2021	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2021	drts	Proceeds From Spac Merger And Pipe Financing Net Of Transaction Cost ProceedsFromSPACMergerAndPIPEFinancingNetOfTransactionCost		usd
CY2023	drts	Proceeds From Spac Merger And Pipe Financing Net Of Transaction Cost ProceedsFromSPACMergerAndPIPEFinancingNetOfTransactionCost		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2021	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2022	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2023	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2021	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2022	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2023	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63534875	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69377922	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001871321

Files In Submission

Name	View Source	Status
0001213900-24-020767-index-headers.html	Edgar Link	pending
0001213900-24-020767-index.html	Edgar Link	pending
0001213900-24-020767.txt	Edgar Link	pending
0001213900-24-020767-xbrl.zip	Edgar Link	pending
drts-20231231.xsd	Edgar Link	pending
ea0200770-20f_alphatau.htm	Edgar Link	pending
ea0200770ex12-1_alphatau.htm	Edgar Link	pending
ea0200770ex12-2_alphatau.htm	Edgar Link	pending
ea0200770ex13-1_alphatau.htm	Edgar Link	pending
ea0200770ex13-2_alphatau.htm	Edgar Link	pending
ea0200770ex15-1_alphatau.htm	Edgar Link	pending
ea0200770ex2-1_alphatau.htm	Edgar Link	pending
ea0200770ex97_alphatau.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
image_031.jpg	Edgar Link	pending
image_032.jpg	Edgar Link	pending
image_033.jpg	Edgar Link	pending
drts-20231231_def.xml	Edgar Link	unprocessable
drts-20231231_lab.xml	Edgar Link	unprocessable
drts-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0200770-20f_alphatau_htm.xml	Edgar Link	completed
image_034.jpg	Edgar Link	pending
image_035.jpg	Edgar Link	pending
image_036.jpg	Edgar Link	pending
image_037.jpg	Edgar Link	pending
image_038.jpg	Edgar Link	pending
image_039.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
drts-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRTS
Alpha Tau Medical Ltd. Stock $drts

2023 Q4 Form 20-F Financial Statement

#000121390024020767 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRTS Alpha Tau Medical Ltd. Stock $drts

2023 Q4 Form 20-F Financial Statement

#000121390024020767 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRTS
Alpha Tau Medical Ltd. Stock $drts